as on January 8, 2026 at 1:38 am IST
Day's Low
Day's High
4.65%
Downside
2.07%
Upside
52 Week's Low
52 Week's High
85.28%
Downside
29.14%
Upside
Check Urogen Pharma Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.0B
EPS (TTM)
-3.1543
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-131.1M
Revenue (TTM)
96.5M
Profit Margin
-170.59%
Return On Equity TTM
-1481.26%
Compare market cap, revenue, PE, and other key metrics of Urogen Pharma Ltd with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.0B | 3.69% | NA | -170.59% | |
| BUY | $37.3B | 414.46% | -16.34 | -264.83% | |
| BUY | $52.6B | 191.54% | 1243.22 | 1.36% | |
| BUY | $115.1B | 101.11% | 31.54 | 31.35% | |
| BUY | $80.9B | 61.38% | 18.28 | 32.13% |
The Urogen Pharma Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Urogen Pharma Ltd investment value today
Current value as on today
₹2,14,366
Returns
₹1,14,366
(+114.37%)
Returns from Urogen Pharma Ltd Stock
₹1,09,657 (+109.66%)
Dollar Returns*
₹4,709 (+4.71%)
Based on 11 analysts
81.82%
Buy
18.18%
Hold
0.00%
Sell
Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for Urogen Pharma Ltd. Average target price of $35.25
Get share price movements and forecasts by analysts on Urogen Pharma Ltd.
What analysts predicted
34.1%UPSIDE
Target Price
$35.25
Current Price
$23.23
Analyzed by
11 Analysts
Target
$35.25
Urogen Pharma Ltd target price $35.25, a slight upside of 34.1% compared to current price of $23.23. According to 11 analysts rating.
Search interest for Urogen Pharma Ltd Stock has increased by 57% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:57% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
![]()
Netprofit is up for the last 2 quarters, -49.94M → -33.34M (in $), with an average increase of 49.8% per quarter
Revenue Rich
![]()
Revenue is up for the last 3 quarters, 20.25M → 27.48M (in $), with an average increase of 14.1% per quarter
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 846.3% return, outperforming this stock by 679.0%
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 164.8% return, outperforming this stock by 67.2%
Price Dip
![]()
In the last 7 days, URGN stock has moved down by -6.5%
| Organisation | Urogen Pharma Ltd |
| Headquarters | 400 Alexander Park Drive, Princeton, NJ, United States, 08540 |
| Industry | Health Technology |
| CEO | Ms. Elizabeth A. Barrett |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations |
Mr. Michael J. Louie M.D., M.P.H., M.Sc. | Executive Vice President of Medical Affairs & Clinical Development |
Mr. David Lin | Chief Commercial Officer |
Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality |
Mr. Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy |
Ms. Elizabeth A. Barrett | President, CEO & Director |
Mr. Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
Mr. Vincent I. Perrone | Senior Director of Investor Relations |
Mr. Bryon Wornson | Executive Vice President of Talent, Advocacy & Communications |
Urogen Pharma Ltd share price today is $23.23 as on . Urogen Pharma Ltd share today touched a day high of $23.71 and a low of $22.15.
Urogen Pharma Ltd share touched a 52 week high of $30 on and a 52 week low of $3.42 on . Urogen Pharma Ltd stock price today i.e. is trending at $23.23,which is 22.57% down from its 52 week high and 579.24% up from its 52 week low.
Urogen Pharma Ltd market capitalisation is $0.00T as on .
Indian investors can start investing in Urogen Pharma Ltd (URGN) shares with as little as ₹89.849 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹898.49 in Urogen Pharma Ltd stock (as per the Rupee-Dollar exchange rate as on ).
Based on Urogen Pharma Ltd share’s latest price of $23.23 as on January 8, 2026 at 1:38 am IST, you will get 0.4305 shares of Urogen Pharma Ltd. Learn more about
fractional shares .
Urogen Pharma Ltd stock has given 3.69% share price returns and 22.88% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?